BioSpace News Archive

Rapport Therapeutics, a clinical-stage biotech aiming to develop precision medicines for neurological disorders, launched Tuesday with $100 million in Series A financing.

Moderna may seek the FDA’s accelerated approval for its personalized cancer vaccine, president Stephen Hoge said Monday.

BridgeBio posted data Monday from its small but highly anticipated Phase II study of infigratinib in achondroplasia - a drug that could give BioMarin a run for its money.

Volastra Therapeutics has in-licensed Amgen’s sovilnesib, a KIF18A inhibitor being studied for high-grade ovarian cancer, triple-negative breast cancer and other solid tumors.

The past two decades were all about nucleic acid reading and writing. The next is about delivering DNA and RNA, Yogev Debbi, CEO of Mana.bio, told BioSpace in an interview.

Merck presented Phase IIb data at ACC Monday showing that its hypercholesterolemia hopeful met the primary endpoint.

POXEL SA, clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic disorders, announced publication in Journal of Hepatology of positive results for DESTINY-1, a 36-week dose-ranging Phase 2 trial.

Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system disorders, announced that it has successfully closed an oversubscribed Series B financing round, raising CHF 103 million from new and existing investors.

MitoRx Therapeutics announces Christine Charman as Chief Development Officer, David Richardson as Finance Director, and four appointments to its Scientific Advisory Board : Prof Chas Bountra, Prof Dame Kay Davies, Prof Laurent Servais, and Dr Bernd C Schwahn.

Chicago Marathon® participants helped orthopaedic researchers further understand the impact of long-distance running on bone and joint health, specifically knee and hip arthritis in recreational runners.